Abstract
optical fibre with a cylindrical end diffuser weeks when treated with neodymium yttrium Photodynamic 0.5-2 cm (400 mW/cm of diffuser) which was ance of superficial tumours. 9 10 Experience except, rarely, for social reasons. They were Professor K Moghissi, indicates that, whereas the YAG laser will in- into smaller bronchi is both easier and safer.
11
Returned to authors 9 May 0 Normal activity without restriction
We report our preliminary experience with recalled 5-7 days later for bronchoscopic ex-Results Seventeen patients (nine men) of mean (SD) amination, debridement, or further treatment to deal with any remaining remnants of tumour. age 69 (9) years (range 45-79) were admitted to the study. They all had inoperable or unEach patient had a further bronchoscopic examination after 5-6 weeks for reassessment of resectable tumours, clinical stage IIIa or IIIb (T3N2 or T4N1). Further pretreatment data the degree of opening of the bronchial lumen and to obtain biopsy specimens and retreat if are shown in table 2. Sixteen patients had primary bronchopulmonary cancers and one required.
All patients were followed up in the out-had a secondary tumour. The overall degree of intraluminal tracheobronchial obstruction patient clinic every 6-8 weeks when they were examined clinically and radiologically and their ranged from 60% to 100%.
Detailed results are shown in table 3. There performance status and pulmonary function were reassessed and recorded. Every three were no procedure-related deaths and only one patient developed a mild photosensitivity remonths (or earlier if indicated) they had a bronchoscopy, the degree of luminal opening action. All patients had their symptoms palliated and all were subjectively satisfied with was assessed, biopsy specimens were obtained, and any retreatment planned. These follow up their treatment. The mean improvements in FVC and FEV 1 were 28% (range 0-90%) and visits continued until the patient died.
Results were recorded after one treatment 25% (range 0-70%), respectively. This was matched by improvement in performance stacycle comprising YAG laser followed by photodynamic therapy had been completed. Relief tus and a mean percentage increase in luminal opening of 66% (range 40-90%). The pathoof symptoms, WHO performance score, and the patient's subjective degree of satisfaction logical response was complete in seven patients for a period of 3-6 months. One patient with were recorded on a simple questionnaire. Pulmonary (ventilation) function, changes in the adenoid cystic carcinoma remained in complete remission for two years and died after 39 chest radiograph, percentage bronchial luminal opening, and pathological response to treat-months of a bladder cancer of different histological type. ment were also recorded.
Complete response to treatment was defined Eleven of the 17 patients (65%) survived for one year and eight (47%) for two years. The as macroscopic and microscopic absence of tumour at endoscopic examination, and partial median survival of the 10 patients who had died by the time of writing was 18.5 months response as a more than 50% reduction in the bulk or extent of the endoluminal tumour.
(range 5-39), 95% CI 9.9 to 29.5. The survival curve for the entire series is shown in fig 1. Figure 1 Survival curve for all the 17 patients in the series.
FVC=forced vital capacity; FEV 1 =forced expiratory volume in one second.
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Discussion
An example of an ideal patient to be treated in this way is case 1 with adenoid cystic carcinoma At most, 20% of all patients with lung cancer limited to the lower trachea, carina, and both are referred for or undergo resection of their bronchi. He had a complete response for 18 tumours.
14 15 External beam radiotherapy or months and eventually died of a second primary chemotherapy, or both, have commonly been cancer (in the bladder) of different histological used to treat unresectable tumours. More retype. cently Nd YAG laser treatment has been shown There is also a case to be made for comto give good relief of symptoms in patients with bination laser treatment as an adjunct to appreciable endoluminal obstruction, but it has chemotherapy and radiotherapy for patients both limitations and drawbacks that emanate with endoluminal tumours and advanced mefrom the fact that light is emitted from the end diastinal extraluminal and lymphatic spread. of its delivery fibre in a straight line. However, The chemotherapy and radiotherapy will target the second and third generation bronchial dithe mediastinal and nodal disease while the visions are not in line with the main stem lasers will destroy the endoluminal lesion. or the lobar bronchial openings so, while the We conclude that patients who, despite their proximal part of the obstructing tumour can inoperable malignant and tracheobronchial obbe evaporated, its distal portion (within a bronstruction (irrespective of histological type), are chial subdivision) may not be safely irradiated.
in reasonably good general condition may well This may account for some of the reported benefit from combined treatment with the YAG complications of bronchoscopic YAG laser laser and photodynamic therapy used setreatment. 
